

GENZYME 2009 GUIDANCE

DESCRIPTION	2009 Guidance	
	Ranges	
Genetic Diseases	\$ 2,405	\$ 2,465
Cardiometabolic and Renal	1,035	1,065
Biosurgery	540	570
Hematologic Oncology	370	395
Other	835	890
TOTAL REVENUE	<u>\$ 5,150</u>	<u>\$ 5,350</u>
*GROSS MARGIN	approx.	75%
*SG&A	approx.	26%
*R&D	approx.	16%
Net Interest / Other	approx.	30
TAX RATE - GAAP	approx.	30%
*TAX RATE - NON-GAAP	approx.	29%
GAAP EPS	approx.	\$ 3.38
AMORTIZATION	approx.	0.70
FAS123R EXPENSE	approx.	0.50
*NON-GAAP EPS		<u>\$ 4.58</u>
WTD AVERAGE DILUTED SHARES O/S	280	282
CAPITAL EXPENDITURES	\$ 600	\$ 650

This financial guidance, which is provided as part of a press release dated March 31, 2009, is subject to all of the qualifications and limitations described therein. Actual results may differ from these forward-looking statements due to the numerous factors described in the press release.

**Non-GAAP excludes the impact of amortization, one-time events and FAS123R expense.*

SELECT PRODUCT GUIDANCE:

Cerezyme	\$ 1,250	\$ 1,275
Fabrazyme	560	570
Myozyme	370	380
Mozobil	40	50
Renagel/Renvela	725	735